GET DAILY SIGNALSWhy Is ARS Pharmaceuticals (SPRY) Stock Up +0.38% Today?
Key Takeaways
- SPRY shares are up about +0.38% in Thursday's session, trading near $2.66 after closing the prior session at $2.65.
- The move follows the company's third-quarter 2026 earnings report released after Wednesday's close, which delivered mixed results against analyst expectations.
- An initial pre-market rally of more than 5% faded during regular trading as investors weighed a revenue and earnings miss against encouraging market-share gains for neffy.
- Analysts delivered a mixed response, with one firm downgrading the stock and another trimming its price target while maintaining an Overweight rating.
- The broader reaction reflects continued uncertainty around commercialization momentum and a stock that remains well below its longer-term moving averages.
- Traders are watching upcoming ARS-2 Phase 2b interim data and the company's full-year 2027 outlook for direction.
- For additional insight, explore Price Targets, Earnings, and Forecast pages on Tickeron for deeper analysis of SPRY.
- To discover AI-driven trading strategies for this and thousands of other tickers, explore Trending AI Robots.
Opening Summary
SPRY, the Nasdaq-listed shares of ARS Pharmaceuticals, Inc., a biopharmaceutical company that develops and commercializes treatments for severe allergic reactions — most notably its needle-free epinephrine nasal spray, neffy — are modestly higher in Thursday's session. The stock is up approximately +0.38%, trading near $2.66 after closing the previous completed session at $2.65. The move represents a confirmation of the stock's upward direction, though it is far more muted than the pre-market jump that followed the company's third-quarter earnings release. Markets attributed the early enthusiasm to neffy's market-share gains and disciplined cost control, before the gains moderated as investors digested a top- and bottom-line miss.
Third-Quarter Earnings Drive the Reaction
The primary catalyst behind Thursday's trading is the company's Q3 2026 earnings report, released after the market closed on Wednesday, November 5. ARS Pharmaceuticals posted a net loss of $0.36 per share, wider than the consensus estimate of a $0.31 loss, while total revenue of $37.7 million came in below the roughly $42 million analysts had expected. U.S. net product revenue for neffy reached $33.4 million, up from $31.3 million a year earlier.
Despite the headline miss, management highlighted several encouraging operating trends. neffy's share of the U.S. epinephrine market surpassed 5%, up from 4% a year ago, and end-user demand rose 42% year over year, with unique prescribers climbing 49% to more than 19,000. Selling, general and administrative expenses fell more than 40% versus the first-half 2026 quarterly average, reflecting a shift away from broad consumer advertising toward targeted provider engagement. The company reaffirmed its goal of reaching cash flow breakeven by the end of 2027.
Analysts Trim Ratings and Price Targets
The earnings report prompted a mixed response from Wall Street, which tempered the stock's early gains. Raymond James downgraded SPRY from Strong Buy to Outperform and lowered its price target from $28 to $17. Cantor Fitzgerald maintained an Overweight rating while reducing its target from $30 to $20. The revisions reflect concerns that net revenue growth lagged the surge in end-user demand, due in part to inventory fluctuations and a gross-to-net figure that remains around 50%. These cautious adjustments likely contributed to the fade from the pre-market high of roughly $2.80 back toward $2.66 during regular trading.
Market Context and Trading Activity
The stock's movement on Thursday is unfolding against a backdrop of significant longer-term pressure. SPRY has fallen roughly 70% over the past 52 weeks and remains well below its 50-day and 200-day moving averages, with a relative strength index in deeply oversold territory. Short interest is also elevated, adding to the potential for volatility around catalyst-driven sessions. Trading activity has been active following the earnings release, though the intraday reversal from pre-market highs suggests the market is balancing the company's operational progress against its continued losses and a commercial strategy reset that is not expected to be fully implemented until early 2027.
What Comes Next for SPRY
Looking ahead, investors will focus on several key milestones for SPRY. The company expects to provide its full-year 2027 financial outlook alongside fourth-quarter results and anticipates interim Phase 2b data for ARS-2, its investigational on-demand treatment for breakthrough flares of chronic spontaneous urticaria, in the first quarter of 2027. Progress on payer coverage, prior-authorization conversion rates, and the rollout of a new marketing campaign in early 2027 will also be closely watched. Key risks include continued net losses, a negative net cash position, and dependence on a single commercialized product, all of which could keep volatility elevated in the shares.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots, highlighting only the strongest performers under current market conditions. Tickeron offers hundreds of these bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and the symbols they trade. For traders seeking a systematic, data-driven approach to navigating volatile names like SPRY, exploring the Trending AI Robots section can provide valuable additional perspective.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
SPRY's Stochastic Oscillator remains in oversold zone for 7 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +6.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where SPRY advanced for three days, in 232 of 283 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
SPRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SPRY as a result. In 76 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for SPRY turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 37 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for SPRY entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.063) is normal, around the industry mean (2.788). P/E Ratio (-1.216) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (3.535) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. SPRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement